By Ludwig Burger GSK on Thursday lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long-acting inj.
Long-acting HIV injections boost GSK growth ambitions news24.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news24.com Daily Mail and Mail on Sunday newspapers.
ViiV Healthcare has received authorisation from the European Commission for Apretude (cabotegravir long-acting (LA) injectable and tablets) to prevent HIV.
Given as few as six times per year, cabotegravir has demonstrated superior efficacy to a daily oral PrEP option in reducing the risk of HIV acquisition in clinical trials.i,ii,iii,iv.